NASDAQ$MASI
Masimo Corp. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Masimo's Q4 2022 earnings were reported, showing revenue growth driven by both healthcare and non-healthcare segments, alongside strategic investments and acquisitions.
Masimo reported consolidated revenue of $617.0 million, representing an 88.3% increase. Healthcare revenue reached $351.9 million, with a 7.4% reported growth and 10.1% constant currency growth. The company's GAAP net income was $41.1 million, or $0.76 per diluted share, and non-GAAP net income was $71.3 million, or $1.32 per diluted share.
- Consolidated revenue reached $617.0 million, up 88.3% year-over-year.
- Healthcare revenue was $351.9 million, representing 7.4% growth and 10.1% on a constant currency basis.
- Non-healthcare revenue totaled $265.1 million.
- GAAP net income was $41.1 million, or $0.76 per diluted share; non-GAAP net income was $71.3 million, or $1.32 per diluted share.
Headline financials
Revenue & EPS history
Masimo · Revenue · Quarterly
$617M
Forward guidance
The Company provided full-year 2023 guidance with consolidated revenue expected to be between $2,415 million and $2,460 million, and earnings per diluted share between $3.59 and $3.69 (GAAP) and $4.70 and $4.80 (Non-GAAP).
Tailwinds
- Consolidated revenue is projected to be between $2,415 million and $2,460 million.
- Healthcare revenue is expected to range from $1,450 million to $1,465 million.
- Non-healthcare revenue is forecasted to be between $965 million and $995 million.
- Consolidated operating profit is anticipated to be between $319 million and $324 million (GAAP) and $400 million to $405 million (Non-GAAP).
- Consolidated earnings per diluted share are projected to be between $3.59 and $3.69 (GAAP) and $4.70 and $4.80 (Non-GAAP).
Headwinds
- First quarter healthcare revenue guidance includes year-over-year foreign currency headwinds of $5.0 million.
- Full-year healthcare revenue guidance includes year-over-year foreign currency headwinds of $3.0 million.
- Uncertainties related to global economic and marketplace conditions.
- Dependence on Masimo SET® and Masimo rainbow SET™ products and technologies for substantially all of the revenue.
- Highly competitive nature of the markets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.6%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+1.6%
Avg return
30 days after
54%
35 / 65 earnings
Positive
+17.2%
Q2 2024
Best reaction
-35.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +0.1% | +0.4% | |
| Q4 2025 | +0.1% | +7.4% | +0.6% | |
| Q3 2025 | -4.8% | -3.0% | -4.9% | |
| Q1 2025 | -6.5% | +1.3% | +6.5% | |
| Q4 2024 | +12.3% | +12.4% | -3.5% | |
| Q3 2024 | +13.7% | +10.2% | +14.9% | |
| Q2 2024 | +17.2% | +21.1% | +9.0% | |
| Q1 2024 | -13.0% | -11.8% | -9.6% | |
| Q4 2023 | -1.5% | -3.2% | +12.4% | |
| Q3 2023 | +2.5% | +6.6% | +30.5% | |
| Q2 2023 | -4.1% | -7.6% | -11.8% | |
| Q1 2023 | -7.0% | -8.0% | -16.1% | |
| Q4 2022 | +4.1% | +7.9% | +5.6% | |
| Q3 2022 | -12.1% | +3.1% | +10.1% | |
| Q2 2022 | +2.1% | -0.2% | -0.4% | |
| Q1 2022 | +7.5% | +8.5% | +19.8% | |
| Q4 2021 | -35.8% | -31.3% | -29.9% | |
| Q3 2021 | +1.4% | -0.7% | +0.1% | |
| Q2 2021 | -0.6% | +2.3% | +3.8% | |
| Q1 2021 | -6.9% | -5.5% | -12.4% | |
| Q4 2020 | +0.5% | +0.3% | -9.6% | |
| Q3 2020 | -5.1% | -9.0% | -0.3% | |
| Q2 2020 | -7.2% | -6.6% | -6.7% | |
| Q1 2020 | -0.6% | +1.7% | +9.3% | |
| Q4 2019 | +0.2% | -4.5% | -14.5% | |
| Q3 2019 | -1.5% | -2.2% | +4.7% | |
| Q2 2019 | -2.8% | -7.8% | -3.2% | |
| Q1 2019 | -1.5% | +1.1% | -2.9% | |
| Q4 2018 | +1.3% | +3.9% | +5.5% | |
| Q3 2018 | -2.2% | -3.3% | -4.5% | |
| Q2 2018 | +8.9% | +9.1% | +18.6% | |
| Q1 2018 | +4.3% | +7.6% | +10.2% | |
| Q4 2017 | +2.2% | -1.4% | +2.7% | |
| Q3 2017 | +1.3% | -1.0% | +2.3% | |
| Q2 2017 | -10.3% | -10.8% | -11.5% | |
| Q1 2017 | -14.2% | -17.0% | -12.5% | |
| Q4 2016 | +5.7% | +11.1% | +21.9% | |
| Q3 2016 | +5.5% | +10.7% | +12.3% | |
| Q2 2016 | +9.3% | +6.1% | +14.0% | |
| Q1 2016 | +7.7% | — | — | |
| Q4 2015 | +5.7% | — | — | |
| Q3 2015 | +4.0% | — | — | |
| Q2 2015 | +6.2% | — | — | |
| Q1 2015 | +1.0% | — | — | |
| Q4 2014 | +8.0% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2014 | -11.2% | — | — | |
| Q1 2014 | -9.1% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | -9.2% | — | — | |
| Q2 2013 | +5.5% | — | — | |
| Q1 2013 | +7.5% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | -6.2% | — | — | |
| Q1 2012 | -6.6% | — | — | |
| Q4 2009 | -3.8% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2011 | +1.1% | — | — | |
| Q2 2011 | -8.4% | — | — | |
| Q1 2011 | +4.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +1.1% | — | — | |
| Q4 2010 | +1.1% | — | — | |
| Q1 2010 | +2.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro